Does the media favor VERA or CYTK?

In the previous week, Cytokinetics had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 23 mentions for Cytokinetics and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Cytokinetics' score of 0.79 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VERA or KRYS?

In the previous week, Krystal Biotech had 16 more articles in the media than Vera Therapeutics. MarketBeat recorded 20 mentions for Krystal Biotech and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Krystal Biotech's score of 1.17 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 13 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RDY or VERA?

Vera Therapeutics has a consensus price target of $84.58, suggesting a potential upside of 163.50%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Vera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.77

Does the media prefer RDY or VERA?

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Dr. Reddy's Laboratories' score of 0.69 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, VERA or NUVL?

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is VERA or NUVL more profitable?

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -74.86% -60.18% Nuvalent N/A -40.11% -35.43%

Does the media favor VERA or NUVL?

In the previous week, Vera Therapeutics had 3 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Vera Therapeutics and 1 mentions for Nuvalent. Vera Therapeutics' average media sentiment score of 1.33 beat Nuvalent's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer KYMR or VERA?

In the previous week, Kymera Therapeutics had 6 more articles in the media than Vera Therapeutics. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Kymera Therapeutics' score of 0.75 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vera Therapeutics (VERA) Competitors

$32.42 +0.32 (+1.00%)

As of 08:59 AM Eastern

Compare

VERA vs. CYTK, KRYS, RDY, NUVL, and KYMR

Should you buy Vera Therapeutics stock or one of its competitors? MarketBeat compares Vera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vera Therapeutics include Cytokinetics (CYTK), Krystal Biotech (KRYS), Dr. Reddy's Laboratories (RDY), Nuvalent (NUVL), and Kymera Therapeutics (KYMR).

How does Vera Therapeutics compare to Cytokinetics?

Vera Therapeutics (NASDAQ:VERA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

99.2% of Vera Therapeutics shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vera Therapeutics presently has a consensus target price of $84.58, indicating a potential upside of 163.50%. Cytokinetics has a consensus target price of $99.90, indicating a potential upside of 29.52%. Given Vera Therapeutics' higher probable upside, research analysts plainly believe Vera Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95

In the previous week, Cytokinetics had 19 more articles in the media than Vera Therapeutics. MarketBeat recorded 23 mentions for Cytokinetics and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Cytokinetics' score of 0.79 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market.

Vera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Cytokinetics	$105.82M	90.70	-$784.96M	-$6.84	N/A

Vera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Cytokinetics	-784.02%	N/A	-52.86%

Summary

Vera Therapeutics beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Krystal Biotech?

Vera Therapeutics (NASDAQ:VERA) and Krystal Biotech (NASDAQ:KRYS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Vera Therapeutics presently has a consensus target price of $84.58, indicating a potential upside of 163.50%. Krystal Biotech has a consensus target price of $360.67, indicating a potential upside of 5.73%. Given Vera Therapeutics' higher possible upside, equities analysts clearly believe Vera Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Krystal Biotech has a net margin of 53.92% compared to Vera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Krystal Biotech had 16 more articles in the media than Vera Therapeutics. MarketBeat recorded 20 mentions for Krystal Biotech and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Krystal Biotech's score of 1.17 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vera Therapeutics has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Krystal Biotech	$389.13M	25.84	$204.83M	$7.48	45.60

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Krystal Biotech beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Vera Therapeutics has a consensus price target of $84.58, suggesting a potential upside of 163.50%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to Vera Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%
Vera Therapeutics	N/A	-74.86%	-60.18%

Dr. Reddy's Laboratories has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	2.76	$456M	$0.44	26.92
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

In the previous week, Dr. Reddy's Laboratories had 3 more articles in the media than Vera Therapeutics. MarketBeat recorded 7 mentions for Dr. Reddy's Laboratories and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Dr. Reddy's Laboratories' score of 0.69 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.9% of Dr. Reddy's Laboratories shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are owned by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Dr. Reddy's Laboratories beats Vera Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Nuvalent?

Vera Therapeutics (NASDAQ:VERA) and Nuvalent (NASDAQ:NUVL) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Nuvalent is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

Nuvalent's return on equity of -40.11% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Nuvalent	N/A	-40.11%	-35.43%

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Nuvalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vera Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

In the previous week, Vera Therapeutics had 3 more articles in the media than Nuvalent. MarketBeat recorded 4 mentions for Vera Therapeutics and 1 mentions for Nuvalent. Vera Therapeutics' average media sentiment score of 1.33 beat Nuvalent's score of 0.00 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vera Therapeutics presently has a consensus target price of $84.58, indicating a potential upside of 163.50%. Nuvalent has a consensus target price of $127.73, indicating a potential upside of 3.04%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Summary

Vera Therapeutics beats Nuvalent on 10 of the 13 factors compared between the two stocks.

How does Vera Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Vera Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	165.23	-$311.35M	-$3.57	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A

Vera Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Vera Therapeutics	N/A	-74.86%	-60.18%

99.2% of Vera Therapeutics shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Kymera Therapeutics had 6 more articles in the media than Vera Therapeutics. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.33 beat Kymera Therapeutics' score of 0.75 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics presently has a consensus target price of $124.48, indicating a potential upside of 20.39%. Vera Therapeutics has a consensus target price of $84.58, indicating a potential upside of 163.50%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Kymera Therapeutics has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market.

Summary

Kymera Therapeutics beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.30B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-5.79	7.38	282.30	24.66
Price / Sales	N/A	1,203.55	564.25	75.48
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	3.79	16.95	10.98	6.07
Net Income	-$299.61M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-8.75%	-1.81%	-0.60%	-0.44%
1 Month Performance	-22.09%	-8.43%	-5.19%	-4.81%
1 Year Performance	53.22%	48.41%	62.02%	18.61%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	3.3785 of 5 stars	$32.42 +1.0%	$84.58 +160.9%	+53.2%	$2.33B	N/A	N/A	40	Positive News Upcoming Earnings Gap Up
CYTK Cytokinetics	3.4909 of 5 stars	$80.62 -0.1%	$99.90 +23.9%	+110.2%	$10.05B	$105.82M	N/A	250	Positive News Upcoming Earnings
KRYS Krystal Biotech	3.2734 of 5 stars	$351.82 +5.0%	$360.67 +2.5%	+117.3%	$9.88B	$389.13M	47.03	210	News Coverage Positive News Earnings Report Gap Up
RDY Dr. Reddy's Laboratories	2.5423 of 5 stars	$11.79 0.0%	N/A	-15.1%	$9.84B	$3.58B	26.78	27,527
NUVL Nuvalent	1.6794 of 5 stars	$123.96 flat	$127.73 +3.0%	N/A	$9.79B	N/A	N/A	40	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. CYTK, KRYS, RDY, NUVL, and KYMR

How does Vera Therapeutics compare to Cytokinetics?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Summary

How does Vera Therapeutics compare to Dr. Reddy's Laboratories?

Summary

How does Vera Therapeutics compare to Nuvalent?

Summary

How does Vera Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. CYTK, KRYS, RDY, NUVL, and KYMR

How does Vera Therapeutics compare to Cytokinetics?

Do institutionals and insiders believe in VERA or CYTK?

Do analysts prefer VERA or CYTK?

Does the media favor VERA or CYTK?

Which has more risk and volatility, VERA or CYTK?

Which has better valuation & earnings, VERA or CYTK?

Is VERA or CYTK more profitable?

Summary

How does Vera Therapeutics compare to Krystal Biotech?

Do analysts rate VERA or KRYS?

Is VERA or KRYS more profitable?

Does the media favor VERA or KRYS?

Which has more volatility & risk, VERA or KRYS?

Which has better earnings and valuation, VERA or KRYS?

Do institutionals and insiders believe in VERA or KRYS?

Summary

How does Vera Therapeutics compare to Dr. Reddy's Laboratories?

Do analysts prefer RDY or VERA?

Which has more volatility & risk, RDY or VERA?

Is RDY or VERA more profitable?

Which has preferable valuation and earnings, RDY or VERA?

Does the media prefer RDY or VERA?

Do insiders & institutionals hold more shares of RDY or VERA?

Summary

How does Vera Therapeutics compare to Nuvalent?

Which has better earnings and valuation, VERA or NUVL?

Is VERA or NUVL more profitable?

Do insiders and institutionals have more ownership in VERA or NUVL?

Which has more volatility & risk, VERA or NUVL?

Does the media favor VERA or NUVL?

Do analysts recommend VERA or NUVL?

Summary

How does Vera Therapeutics compare to Kymera Therapeutics?

Which has preferable earnings & valuation, KYMR or VERA?

Is KYMR or VERA more profitable?

Do institutionals & insiders believe in KYMR or VERA?

Does the media prefer KYMR or VERA?

Do analysts recommend KYMR or VERA?

Which has more risk and volatility, KYMR or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools